Search Result
Results for "
short-acting
" in MedChemExpress (MCE) Product Catalog:
12
Isotope-Labeled Compounds
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-B0422
-
|
A4166; Senaglinide
|
Potassium Channel
Dipeptidyl Peptidase
|
Metabolic Disease
|
|
Nateglinide, a D-phenylalanine derivative, is an orally active and short-acting insulinotropic agent and a DPP IV inhibitor. Nateglinide inhibits ATP-sensitive K + channels in pancreatic β-cells. Nateglinide is used for the treatment of type 2 (non-insulin-dependent) diabetes mellitus .
|
-
-
- HY-B0422S
-
|
A4166 d5; Senaglinide d5
|
Potassium Channel
Dipeptidyl Peptidase
|
Metabolic Disease
|
|
Nateglinide-d5 is a deuterium labeled Nateglinide. Nateglinide, a D-phenylalanine derivative, is an orally active and short-acting insulinotropic agent and a DPP IV inhibitor. Nateglinide inhibits ATP-sensitive K+ channels in pancreatic β-cells. Nateglinide is used for the treatment of type 2 (non-insulin-dependent) diabetes mellitus[1][2].
|
-
-
- HY-B0507A
-
-
-
- HY-B0507
-
-
-
- HY-B1288A
-
|
Benoxinate; Novesinol; Oxybucaine
|
Others
|
Inflammation/Immunology
|
|
Oxybuprocaine is a short-acting ester-type local anesthetic agent used in ophthalmology and otolaryngology .
|
-
-
- HY-17436
-
-
-
- HY-B0436
-
-
-
- HY-B0422R
-
|
A4166 (Standard); Senaglinide (Standard)
|
Potassium Channel
Dipeptidyl Peptidase
|
Metabolic Disease
|
|
Nateglinide (Standard) is the analytical standard of Nateglinide. This product is intended for research and analytical applications. Nateglinide, a D-phenylalanine derivative, is an orally active and short-acting insulinotropic agent and a DPP IV inhibitor. Nateglinide inhibits ATP-sensitive K + channels in pancreatic β-cells. Nateglinide is used for the treatment of type 2 (non-insulin-dependent) diabetes mellitus .
|
-
-
- HY-17457
-
-
-
- HY-101939
-
|
|
LPL Receptor
|
Neurological Disease
|
|
RP-001 is a picomolar short-acting S1P1 (EDG1) selective agonist, with an EC50 of 9 pM. RP-00 induces internalization and polyubiquitination of S1P1. RP-001 has little activity on S1P2-S1P4 and only moderate affinity for S1P5 .
|
-
-
- HY-101939A
-
|
|
LPL Receptor
|
Neurological Disease
|
|
RP-001 hydrochloride is a picomolar short-acting S1P1 (EDG1) selective agonist, with an EC50 of 9 pM. RP-00 hydrochloride induces internalization and polyubiquitination of S1P1. RP-001 hydrochloride has little activity on S1P2-S1P4 and only moderate affinity for S1P5 .
|
-
-
- HY-B0507S
-
-
-
- HY-B0304AS
-
|
LY-210448-d7 hydrochloride
|
Serotonin Transporter
|
Neurological Disease
|
|
Dapoxetine-d7 (hydrochloride) is the deuterium labeled Dapoxetine hydrochloride. Dapoxetine hydrochloride is a short-acting selective serotonin reuptake inhibitor (SSRI)[1].
|
-
-
- HY-15105
-
|
|
CaSR
|
Inflammation/Immunology
|
|
SB-423562 is a short-acting calcium-sensing receptor (CaR) antagonist. SB-423562 has the potential for osteoporosis research.
|
-
-
- HY-B1481B
-
|
Isoetarine hydrochloride
|
Others
|
Infection
|
|
Isoetharine hydrochloride is selective, short-acting and orally active β-agonist which is widely used as a bronchodilator in the research of inhalation research .
|
-
-
- HY-15105A
-
|
|
CaSR
|
Inflammation/Immunology
|
|
SB-423562 hydrochloride is a short-acting calcium-sensing receptor (CaR) antagonist. SB-423562 hydrochloride has the potential for osteoporosis research.
|
-
-
- HY-B1784
-
|
Sulfaisodimidine
|
Bacterial
Antibiotic
|
Infection
|
|
Sulfisomidin (Sulfaisodimidine) is an orally active short-acting sulfonamide antibacterial. Sulfisomidin can be used for the research of lower urinary tract infections .
|
-
-
- HY-16472
-
|
|
Antibiotic
Bacterial
|
Infection
|
|
Sulfacytine is a short-acting sulfonamide antibiotic. Sulfacytine is active against bacteria and is an effective agent for the research of acute uncomplicated urinary tract infections .
|
-
-
- HY-B0507R
-
|
|
Bacterial
Antibiotic
|
Infection
|
|
Sulfathiazole (Standard) is the analytical standard of Sulfathiazole. This product is intended for research and analytical applications. Sulfathiazole, an organosulfur compound, is used as a short-acting sulfonamide antibiotic .
|
-
-
- HY-B0304AS1
-
-
-
- HY-17436R
-
|
|
Calcium Channel
|
Cardiovascular Disease
Cancer
|
|
Clevidipine (Standard) is the analytical standard of Clevidipine. This product is intended for research and analytical applications. Clevidipine is a short-acting dihydropyridine calcium channel antagonist (IC50= 7.1 nM, V(H) = -40 mV ).
|
-
-
- HY-135230
-
|
FP3FBZ
|
Opioid Receptor
|
Neurological Disease
|
|
LY2444296 is an orally bioavailable, high-affinity and selective short-acting kappa opioid receptor (KOPR) antagonist, with a Ki value of ∼1 nM. LY2444296 exhibits anti-anxiety like effects .
|
-
-
- HY-B0436R
-
-
-
- HY-116457
-
|
Sombrevin; Fabantol
|
GABA Receptor
|
Cardiovascular Disease
Neurological Disease
|
|
Propanidid (Sombrevin; Fabantol) is a γ-aminobutyric acid type A (GABAA) receptor agonist and a short-acting non-barbiturate general agent that can suppress or relieve pain. Propanidid can decrease the arterial pressure .
|
-
-
- HY-B1784R
-
|
|
Bacterial
Antibiotic
|
Infection
|
|
Sulfisomidin (Standard) is the analytical standard of Sulfisomidin. This product is intended for research and analytical applications. Sulfisomidin (Sulfaisodimidine) is an orally active short-acting sulfonamide antibacterial. Sulfisomidin can be used for the research of lower urinary tract infections .
|
-
-
- HY-B1675A
-
|
(R)-Albuterol hydrochloride; (R)-Salbutamol hydrochloride; Levosalbutamol hydrochloride
|
Adrenergic Receptor
|
Inflammation/Immunology
|
|
Levalbuterol ((R)-Albuterol) hydrochloride is a short-acting β2-adrenergic receptor agonist and the active (R)-enantiomer of Salbutamol. Levalbuterol hydrochloride is a more potent bronchodilator than Salbutamol and has the potential for the treatment of COPD .
|
-
-
- HY-106450
-
|
MRE-0470; WRC 0470
|
Adenosine Receptor
|
Cardiovascular Disease
|
|
Binodenoson (MRE-0470) is a potent and selective A2A adenosine receptor agonist (KD=270 nM). Binodenoson is being developed as a short-acting coronary vasodilator as an adjunct to radiotracers for use in myocardial stress imaging .
|
-
-
- HY-17436S1
-
-
-
- HY-B1037S
-
|
Albuterol-d3; AH-3365-d3
|
Adrenergic Receptor
|
Neurological Disease
Endocrinology
|
|
Salbutamol-d3 is the deuterium labeled Salbutamol. Salbutamol is a short-acting β2-adrenergic receptor agonist used for the relief of bronchospasm in conditions such as asthma and chronic obstructive pulmonary disease (COPD).
|
-
-
- HY-B1037S2
-
-
-
- HY-15708
-
|
|
Opioid Receptor
|
Neurological Disease
|
|
LY2795050 is a short-acting selective κκ-opioid receptor (KOR) antagonist. LY2795050 has high affinity for the KOR with Ki value of 0.72 nM. LY2795050 can be used for the research of central nervous system dysfunction .
|
-
-
- HY-B1700A
-
|
|
nAChR
|
Neurological Disease
|
|
Mivacurium dichloride is a benzylisoquinoline derivative and is a short-acting non-depolarizing neuromuscular blocking agent and skeletal muscle relaxant. Mivacurium dichloride couples with the nAChR to reduce or inhibit the depolarizing effect of acetylcholine on the terminal disc of the muscle cell .
|
-
-
- HY-17436S4
-
-
-
- HY-106842
-
|
OR-462
|
COMT
|
Neurological Disease
Inflammation/Immunology
|
|
Nitecapone (OR-462) is an orally active and short-acting catechol-O-methyltransferase (COMT) inhibitor with gastroprotective and antioxidant properties. Nitecapone (OR-462) scavenges reactive oxygen and nitric radicals and prevents lipid peroxidation .
|
-
-
- HY-B1037S3
-
|
Albuterol-d9 acetate; AH-3365-d9 acetate
|
Adrenergic Receptor
|
Endocrinology
|
|
Salbutamol-d9 (acetate) is the deuterium labeled Salbutamol[1]. Salbutamol is a short-acting β2-adrenergic receptor agonist used for the relief of bronchospasm in conditions such as asthma and chronic obstructive pulmonary disease (COPD).
|
-
-
- HY-17436S3
-
|
|
Calcium Channel
|
Cardiovascular Disease
|
|
(R)-Clevidipine- 13C,d3 is the deuterium and 13C labeled Clevidipine[1]. Clevidipine is a short-acting dihydropyridine calcium channel antagonist (IC50= 7.1 nM, V(H) = -40 mV ) under development for treatment of perioperative hypertension[2].
|
-
-
- HY-14232
-
|
|
Calcium Channel
|
Neurological Disease
|
|
TTA-A8 (Compound 13) is a short-acting T-type calcium channel antagonist with oral activity, exhibiting an IC50 value of 31.3 nM in the FLIPR depolarization assay. TTA-A8 possesses favorable pharmacokinetic properties, making it suitable for research on epilepsy and sleep .
|
-
-
- HY-B1675AR
-
|
|
Adrenergic Receptor
|
Inflammation/Immunology
|
|
Levalbuterol (hydrochloride) (Standard) is the analytical standard of Levalbuterol (hydrochloride). This product is intended for research and analytical applications. Levalbuterol ((R)-Albuterol) hydrochloride is a short-acting β2-adrenergic receptor agonist and the active (R)-enantiomer of Salbutamol. Levalbuterol hydrochloride is a more potent bronchodilator than Salbutamol and has the potential for the treatment of COPD .
|
-
-
- HY-15691A
-
|
|
Others
|
Inflammation/Immunology
|
|
PF-4455242 hydrochloride is a selective, short-acting antagonist of the κ-opioid receptor, exhibiting potential analgesic effects. PF-4455242 hydrochloride has been identified through a strategy utilizing parallel chemistry and physicochemical property design. PF-4455242 hydrochloride demonstrated confirmed potency and selectivity in the tail-flick analgesia model.
|
-
-
- HY-B1700AR
-
|
|
nAChR
|
Neurological Disease
|
|
Mivacurium (dichloride) (Standard) is the analytical standard of Mivacurium (dichloride). This product is intended for research and analytical applications. Mivacurium dichloride is a benzylisoquinoline derivative and is a short-acting non-depolarizing neuromuscular blocking agent and skeletal muscle relaxant. Mivacurium dichloride couples with the nAChR to reduce or inhibit the depolarizing effect of acetylcholine on the terminal disc of the muscle cell .
|
-
-
- HY-137494
-
|
|
GABA Receptor
|
Neurological Disease
|
|
Ethyl β-carboline-3-carboxylate (fl-CCE) is a ligand and short-acting antagonist of benzodiazepine receptors. Ethyl β-carboline-3-carboxylate did not affect cerebellar cGMP levels when used alone, but when taken together with Diazepam, it significantly inhibited the cGMP levels that were upregulated by Diazepam .
|
-
-
- HY-B1037
-
|
Albuterol; AH-3365
|
Adrenergic Receptor
ERK
|
Inflammation/Immunology
Cancer
|
|
Salbutamol (Albuterol) is a short-acting beta-2 adrenergic receptor agonist with oral activity. Salbutamol promotes tumorigenesis of gastric cancer cells through the β2-AR/ERK/EMT pathway. Salbutamol is used to study bronchospasms caused by asthma and chronic obstructive pulmonary disease (COPD) .
|
-
-
- HY-17611
-
|
MSP-2017; (-)-MSP-2017
|
Calcium Channel
|
Cardiovascular Disease
|
|
Etripamil (MSP-2017) is a short-acting L-type calcium-channel antagonist, can be used for the research of Paroxysmal Supraventricular Tachycardia (PSVT). Etripamil (MSP-2017) slows atrioventricular nodal conduction and prolongs atrioventricular nodal refractory periods by inhibiting calcium ion influx through the calcium slow channels in the atrioventricular node cells .
|
-
-
- HY-16056
-
|
|
Adrenergic Receptor
|
Cardiovascular Disease
|
|
Arbutamine is a short-acting, potent and nonselective β-adrenoceptor agonist. Arbutamine stimulates cardiac β1-, tracheal β2-, and adiopocyte β3- adrenergic receptors. Arbutamine provides cardiac stress increases heart rate, cardiac contractility, and systolic blood pressure. Arbutamine can be used for cardiac stress agent .
|
-
-
- HY-16056A
-
|
|
Adrenergic Receptor
|
Cardiovascular Disease
|
|
Arbutamine hydrochloride is a short-acting, potent and nonselective β-adrenoceptor agonist. Arbutamine hydrochloride stimulates cardiac β1-, tracheal β2-, and adiopocyte β3- adrenergic receptors. Arbutamine hydrochloride provides cardiac stress increases heart rate, cardiac contractility, and systolic blood pressure. Arbutamine hydrochloride can be used for cardiac stress agent .
|
-
-
- HY-B1037B
-
|
Albuterol adipate; AH-3365 adipate
|
Adrenergic Receptor
ERK
|
Inflammation/Immunology
Cancer
|
|
Salbutamol (Albuterol) adipate is a short-acting beta-2 adrenergic receptor agonist with oral activity. Salbutamol adipate promotes tumorigenesis of gastric cancer cells through the β2-AR/ERK/EMT pathway. Salbutamol adipate is used to study bronchospasms caused by asthma and chronic obstructive pulmonary disease (COPD) .
|
-
-
- HY-14205
-
|
|
Monoamine Oxidase
|
Neurological Disease
|
|
NW-1772 (methanesulfonate) (compound 22b) is a potent and selective monoamine oxidase (MAO) B inhibitor. NW-1772 has some advantages, such as rapid blood-brain barrier penetration, short-acting and reversible inhibitory activity, slight inhibition of selected cytochrome P450s, and low in vitro toxicity. NW-1772 can be used for the research of neurodegenerative diseases .
|
-
-
- HY-B1037R
-
|
Albuterol (Standard); AH-3365 (Standard)
|
Adrenergic Receptor
ERK
|
Inflammation/Immunology
Cancer
|
|
Salbutamol (Standard) is the analytical standard of Salbutamol. This product is intended for research and analytical applications. Salbutamol (Albuterol) is a short-acting beta-2 adrenergic receptor agonist with oral activity. Salbutamol promotes tumorigenesis of gastric cancer cells through the β2-AR/ERK/EMT pathway. Salbutamol is used to study bronchospasms caused by asthma and chronic obstructive pulmonary disease (COPD) .
|
-
-
- HY-B1510
-
-
-
- HY-B1510S
-
-
- HY-B1830
-
|
|
Estrogen Receptor/ERR
|
Endocrinology
|
|
Estradiol enanthate is a shorter-acting estrogen. The combination of Estradiol enanthate and dihydroxyprogesterone acetophenide can be used as a monthly injectable contraceptive .
|
-
- HY-B1510R
-
|
|
Histamine Receptor
|
Inflammation/Immunology
Endocrinology
|
|
Acrivastine (Standard) is the analytical standard of Acrivastine. This product is intended for research and analytical applications. Acrivastine (BW825C) is a short acting histamine 1 receptor antagonist for the treatment of allergic rhinitis.
|
-
- HY-B0321
-
|
Ro 1-7683
|
mAChR
|
Neurological Disease
|
|
Tropicamide (Ro 1-7683) is a selective M4 muscarinic acetylcholine receptor antagonist. Tropicamide produces short acting mydriasis (dilation of the pupil) and cycloplegia when applied as eye drops .
|
-
- HY-B1675
-
|
(R)-Albuterol; (R)-Salbutamol; Levosalbutamol
|
Adrenergic Receptor
|
Inflammation/Immunology
|
|
Levalbuterol ((R)-Albuterol; (R)-Salbutamol) is a short-acting β2-adrenergic receptor agonist and the active (R)-enantiomer of Salbutamol. Levalbuterol is a more potent bronchodilator than Salbutamol and has the potential for the treatment of COPD .
|
-
- HY-129451
-
|
|
Others
|
Others
|
|
HIE-124 is a potent ultra-short acting hypnotic that exhibits a rapid onset of action and a shorter duration of action with no acute tolerance or noticeable side effects. HIE-124 is promising for research of preanesthetic medication and anesthesia inducer .
|
-
- HY-127128
-
|
ACC-9089 sulfate
|
Adrenergic Receptor
|
Neurological Disease
|
|
Flestolol (ACC-9089) sulfate is a competitive, ultra-short-acting beta-adrenergic blocking agent. Flestolol sulfate shows a half-life of approximately 6.5 minutes. Flestolol sulfate has the potential for the research of chest pain .
|
-
- HY-121814A
-
|
(R)-Acenocoumarin; (R)-Nicoumalone
|
Others
|
Others
|
|
(R)-Acenocoumarol ((R)-Acenocoumarin; (R)-Nicoumalone) is a short-acting oral anticoagulant that, like warfarin, works by inhibiting vitamin K epoxide reductase. In vitro evaluations have shown that (R)-Acenocoumarol ((R)-Acenocoumarin; (R)-Nicoumalone) has a higher intrinsic anticoagulant potency than warfarin and phenprocoumon. (R)-Acenocoumarol ((R)-Acenocoumarin; (R)-Nicoumalone) has a single chiral center that produces two different enantiomeric forms. (R)-(R)-Acenocoumarol ((R)-Acenocoumarin; (R)-Nicoumalone) has a longer plasma elimination half-life (6.6 hours) and a slower plasma clearance rate (1.9 L/hour) compared to the (S)-enantiomer (1.8 hours, 28.5 L/hour). (R)-(R)-Acenocoumarol ((R)-Acenocoumarin; (R)-Nicoumalone) is a more potent anticoagulant in vivo than the (S)-enantiomer.
|
-
- HY-100607A
-
|
ONO1101 hydrochloride
|
Adrenergic Receptor
|
Cardiovascular Disease
Endocrinology
|
|
Landiolol hydrochloride (ONO1101 hydrochloride) is a highly beta1 selective ultra-short acting beta-blocker (β1/β2 selectivity = 255:1, a half-life of 4 min)， acts as an adrenoceptor antagonist .
|
-
- HY-B0321S
-
|
Ro 1-7683-d3
|
mAChR
|
Neurological Disease
|
|
Tropicamide-d3 is the deuterium labeled Tropicamide[1]. Tropicamide (Ro 1-7683) is a selective M4 muscarinic acetylcholine receptor antagonist. Tropicamide produces short acting mydriasis (dilation of the pupil) and cycloplegia when applied as eye drops[2][3].
|
-
- HY-B0321R
-
|
Ro 1-7683 (Standard)
|
mAChR
|
Neurological Disease
|
|
Tropicamide (Standard) is the analytical standard of Tropicamide. This product is intended for research and analytical applications. Tropicamide (Ro 1-7683) is a selective M4 muscarinic acetylcholine receptor antagonist. Tropicamide produces short acting mydriasis (dilation of the pupil) and cycloplegia when applied as eye drops .
|
-
- HY-100607
-
-
- HY-100607AR
-
|
|
Adrenergic Receptor
|
Cardiovascular Disease
Endocrinology
|
|
Landiolol (hydrochloride) (Standard) is the analytical standard of Landiolol (hydrochloride). This product is intended for research and analytical applications. Landiolol hydrochloride (ONO1101 hydrochloride) is a highly beta1 selective ultra-short acting beta-blocker (β1/β2 selectivity = 255:1, a half-life of 4 min)， acts as an adrenoceptor antagonist .
|
-
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P1810
-
|
|
Peptides
|
Neurological Disease
|
|
c(Bua-Cpa-Thi-Val-Asn-Cys)-Pro-Agm is a is a potent, selective and short-acting peptidic V2 receptor (V2R) agonist with EC50s of 0.25 and 0.05 nM for hV2R and rV2R, respectively .
|
-
- HY-P1809
-
|
c(Bua-Cpa-Thi-Val-Asn-Cys)-Pro-d-Arg-NEt2
|
Peptides
|
Metabolic Disease
|
|
Velmupressin (c(Bua-Cpa-Thi-Val-Asn-Cys)-Pro-d-Arg-NEt2) is a potent, selective and short-acting peptidic V2 receptor (V2R) agonist with EC50s of 0.07 and 0.02 nM for hV2R and rV2R, respectively .
|
-
- HY-P1809A
-
|
c(Bua-Cpa-Thi-Val-Asn-Cys)-Pro-d-Arg-NEt2 acetate
|
Peptides
|
Metabolic Disease
|
|
Velmupressin (c(Bua-Cpa-Thi-Val-Asn-Cys)-Pro-d-Arg-NEt2) acetate is a potent, selective and short-acting peptidic V2 receptor (V2R) agonist with EC50s of 0.07 and 0.02 nM for hV2R and rV2R, respectively .
|
| Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
| Cat. No. |
Product Name |
Chemical Structure |
-
- HY-B0422S
-
|
|
|
Nateglinide-d5 is a deuterium labeled Nateglinide. Nateglinide, a D-phenylalanine derivative, is an orally active and short-acting insulinotropic agent and a DPP IV inhibitor. Nateglinide inhibits ATP-sensitive K+ channels in pancreatic β-cells. Nateglinide is used for the treatment of type 2 (non-insulin-dependent) diabetes mellitus[1][2].
|
-
-
- HY-B0304AS
-
|
|
|
Dapoxetine-d7 (hydrochloride) is the deuterium labeled Dapoxetine hydrochloride. Dapoxetine hydrochloride is a short-acting selective serotonin reuptake inhibitor (SSRI)[1].
|
-
-
- HY-B1037S
-
|
|
|
Salbutamol-d3 is the deuterium labeled Salbutamol. Salbutamol is a short-acting β2-adrenergic receptor agonist used for the relief of bronchospasm in conditions such as asthma and chronic obstructive pulmonary disease (COPD).
|
-
-
- HY-B1037S2
-
|
|
|
Salbutamol-d9 is the deuterium labeled Salbutamol. Salbutamol is a short-acting β2-adrenergic receptor agonist used for the relief of bronchospasm in conditions such as asthma and chronic obstructive pulmonary disease (COPD).
|
-
-
- HY-B0507S
-
|
|
|
Sulfathiazole-d4 is a deuterium labeled Sulfathiazole. Sulfathiazole, an organosulfur compound, is used as a short-acting sulfonamide antibiotic[1].
|
-
-
- HY-B0304AS1
-
|
|
|
Dapoxetine-d6 (LY-210448-d6) hydrochloride is the deuterium labeled Dapoxetine hydrochloride. Dapoxetine hydrochloride is a short-acting selective serotonin reuptake inhibitor (SSRI)
|
-
-
- HY-17436S1
-
|
|
|
Clevidipine-d7 is the deuterium labeled Clevidipine. Clevidipine is a short-acting dihydropyridine calcium channel antagonist (IC50= 7.1 nM, V(H) = -40 mV ) under development for treatment of perioperative hypertension[1][2].
|
-
-
- HY-17436S4
-
|
|
|
Clevidipine- 15N,d10 is 15N and deuterated labeled Clevidipine (HY-17436). Clevidipine is a short-acting dihydropyridine calcium channel antagonist (IC50= 7.1 nM, V(H)=-40 mV ).
|
-
-
- HY-B1037S3
-
|
|
|
Salbutamol-d9 (acetate) is the deuterium labeled Salbutamol[1]. Salbutamol is a short-acting β2-adrenergic receptor agonist used for the relief of bronchospasm in conditions such as asthma and chronic obstructive pulmonary disease (COPD).
|
-
-
- HY-17436S3
-
|
|
|
(R)-Clevidipine- 13C,d3 is the deuterium and 13C labeled Clevidipine[1]. Clevidipine is a short-acting dihydropyridine calcium channel antagonist (IC50= 7.1 nM, V(H) = -40 mV ) under development for treatment of perioperative hypertension[2].
|
-
-
- HY-B1510S
-
|
|
|
Acrivastine-d7 is a deuterium labeled Acrivastine. Acrivastine is a short acting histamine 1 receptor antagonist.
|
-
-
- HY-B0321S
-
|
|
|
Tropicamide-d3 is the deuterium labeled Tropicamide[1]. Tropicamide (Ro 1-7683) is a selective M4 muscarinic acetylcholine receptor antagonist. Tropicamide produces short acting mydriasis (dilation of the pupil) and cycloplegia when applied as eye drops[2][3].
|
-
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent:
